Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of relapsed/refractory multiple myeloma. The current Food and Drug Administration approved CAR T cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel both target B cell maturation antigen (BCMA), wh...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Kevin Miller, Hamza Hashmi, Sridevi Rajeeve
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-05-01
Subjects:	multiple myeloma CAR T cell therapy chimeric antigen receptor non-BCMA immunotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1398902/full